Governance
The Board of Directors at the Diabetes Innovation and Impact Foundation (DIIF) is composed of accomplished professionals who bring a wealth of expertise. These expertise include:
- Law
- Medicine
- Finance
- Governance
- Public health, and
- Community leadership
Their diverse backgrounds enables a strong oversight and informed decision-making across DIIF’s innovative initiatives while remaining responsive to the needs of the diabetes community as well as maintaining the highest standards of accountability and impact.
DIIF Board of Directors
-
Richard Loveridge
BComm, LLB, Grad Dip Applied Finance, FINSIA
Special responsibilities: Chair of Audit and Risk Committee; and Chair of Commercial Committee.
Elected 2019 and elected President 2022.
-
Kathryn Arndt
BBus (HRM), Graduate Diploma (Bus),
Member of the Australian Institute of Company DirectorsSpecial responsibilities: Audit and Risk Committee; Commercial Committee; and Executive Committee.
Elected 2007.
-
Professor Peter Colman AM
MBBS, FRACP, MD
Special responsibilities: Chair of Clinical Advisory Committee.
Elected 2014.
-
Erin Ferraris
BComm, MPA
Special responsibilities: Audit and Risk Committee; and Commercial Committee.
Board Observer in 2019 and appointed to the Board in 2020 and elected 2021.
-
Anthony Howard AM KC
B.Juris/LLB, DipCrim
In October 2024, Mr Howard was appointed as a Director of the Essendon Football Club (having been founding chair of the Lawdons coterie).
-
Dan Jefferson
BA (Hons) European Studies
Graduate of the Australian Institute of Company DirectorsSpecial responsibilities: Programs & Services Committee
Appointed in 2022.
-
Victoria Stevenson
RN Grad Dip Education (Health Education) CDE FACN
Special responsibilities: Programs and Services Committee and Clinical Advisory Committee.
Elected 2011.
-
Ed Stockdale
BBus, Fellow CPA, Fellow AICD, Fellow GIA, Fellow CI
Special responsibilities: Audit and Risk Committee; and Commercial Committee.
Elected 2012.
-
Dr. Sarah Price
MBBS(H1) FRACP PhD DipRANZCOG DCH CertObMed
Special responsibilities: Clinical Advisory Committee.
Elected 2025.